GlassScriptPhysician profile
Manuel Ozambela
NPI 1770945826
$16,207.24
in general payments reported to CMS, 2019-2025
15 companies · $4,908 in 2025
The $4,908 reported for 2025 was more than what 90% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.58 · 2022: $145 · 2023: $143 · 2024: $11K · 2025: $4,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,500 · Consulting Fee: $3,779 · Travel and Lodging: $3,596 · Food and Beverage: $2,100 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,500.00 |
| Consulting Fee | $3,778.68 |
| Travel and Lodging | $3,595.80 |
| Food and Beverage | $2,100.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,045.47 | 2024-2025 | |
| Ethicon INC. | $2,653.65 | 2024 | |
| Avyxa Pharma, LLC | $2,649.74 | 2025 | |
| Ethicon US, LLC | $1,470.00 | 2024 | Evarrest, Surgiflo Hemostatic Matrix, Dermabond Prineo |
| Angiodynamics, INC. | $1,277.83 | 2023-2025 | Nanoknife |
| Ferring Pharmaceuticals INC. | $541.63 | 2024-2025 | Adstiladrin |
| Boston Scientific Corporation | $145.17 | 2022 | |
| Olympus America INC. | $116.51 | 2024 | Itind System |
| Astellas Pharma US INC | $78.58 | 2021 | |
| Novartis Pharmaceuticals Corporation | $61.29 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $58.04 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $37.26 | 2025 | Keytruda, Welireg |
| Janssen Biotech, INC. | $26.00 | 2023 | Erleada, Rybrevant |
| Urogen Pharma, INC. | $23.07 | 2025 | |
| Fennec Pharmaceuticals, INC. | $23.00 | 2025 | Fyarro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Ozambela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.